Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
03
05
2023
accepted:
21
11
2023
medline:
24
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that can lead to irreversible loss of vision. Intravenous thrombolysis (IVT) has been used experimentally for its treatment. Our study aimed to evaluate the effect of emergency IVT on CRAO and its impact on visual acuity outcomes. We conducted a retrospective observational study of patients with CRAO. A total of 46 patients with CRAO were analysed; 16 patients received IVT treatment (IVT group) while 30 did not (no-IVT group). Seven patients from the IVT group received IVT early, within 4.5 hours (h) after the onset of symptoms (early-IVT), and 9 patients received it beyond this timeframe (late-IVT). The median time-to-hospital was 8.5 h: 3 h for the IVT group and 24 h for the no-IVT group. The median time-to-treatment was 5 h. The median outcome of visual acuity was 0.05 in the early-IVT, 0.025 in the late-IVT, and 0.01 in the no-IVT group. Among patients who received IVT early, 86% exhibited significant visual improvement. This improvement was four-fold greater compared to all other groups (p = 0.040), including the late-IVT (p = 0.011) and no-IVT groups (p = 0.023). No complications of the treatment were reported. Our study confirms that the administration of IVT treatment for CRAO within the 4.5-h time window is both safe and effective.
Identifiants
pubmed: 37993533
doi: 10.1038/s41598-023-47987-9
pii: 10.1038/s41598-023-47987-9
pmc: PMC10665428
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20505Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 00064203
Informations de copyright
© 2023. The Author(s).
Références
Eur Stroke J. 2021 Mar;6(1):I-LXII
pubmed: 33817340
Int J Stroke. 2017 Oct;12(7):720-723
pubmed: 28067616
Stroke. 2011 Aug;42(8):2229-34
pubmed: 21757667
Stroke. 2020 Jul;51(7):2018-2025
pubmed: 32568646
Cerebrovasc Dis. 2011;32(4):307-20
pubmed: 21921593
J Refract Surg. 1997 Jul-Aug;13(4):388-91
pubmed: 9268940
Stroke. 2020 Feb;51(2):687-695
pubmed: 31865896
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Ophthalmol Ther. 2021 Dec;10(4):715-730
pubmed: 34169468
PLoS One. 2018 May 29;13(5):e0198114
pubmed: 29813111
Ophthalmology. 2002 Apr;109(4):744-7; discussion 747-8
pubmed: 11927432
Prog Retin Eye Res. 2015 Nov;49:82-119
pubmed: 26113210
Ophthalmology. 2010 Jul;117(7):1367-75.e1
pubmed: 20609991
JAMA Neurol. 2015 Oct;72(10):1148-54
pubmed: 26258861
Stroke. 2020 Mar;51(3):800-807
pubmed: 31951154
Am J Ophthalmol. 2018 Dec;196:96-100
pubmed: 30153430
Am J Ophthalmol. 2005 Sep;140(3):376-91
pubmed: 16138997
Stroke. 2021 Jun;52(6):e282-e294
pubmed: 33677974